Ximedica, a Providence, RI-based a full-service product development firm exclusively focused on medical technology, has received a majority investment from SV Life Sciences.
Co-Founders Stephen Lane and Aidan Petrie sold its shares in the transaction, whose amount was not disclosed. President & CEO Randall S. Barko and the current management team will remain in place, and Aidan Petrie will continue as Chief Innovation Officer. Paul LaViolette, Managing Partner and Chief Operating Officer at SV Life Sciences, will join as Chairman of Ximedica’s board.
Ximedica is a full service ISO 13485 certified and FDA registered product development firm that focuses exclusively on the development and commercialization of medical devices.
It serves medical and pharmaceutical companies as well as emergent start-ups.
It has offices in Providence, Minneapolis, Boston, Chicago and Hong Kong.
FinSMEs
05/11/ 2014